Reviral Ltd - Revitalising antivirals

Leading the Small Molecule Fight against RSV

Driving small molecule antiviral development for RSV (Respiratory Syncytial Virus) infection

RSV: Serious Unmet Medical Need

RSV is a common and serious cause of respiratory infection in children, the immune-compromised and the elderly
The World Health Organization (WHO) estimates that RSV causes 64 million infections and 160,000 infant deaths each year
It is the most important respiratory virus, responsible for one-fifth of all lower respiratory tract infections worldwide
RSV infection is responsible for more infant hospitalisations than other viral infections such as influenza
There are no effective treatments or vaccines available against RSV
It represents a significant unmet medical need

Leading the Way: RV521

An RSV fusion (F) protein inhibitor
Best-in-class drug to treat RSV infections
Completed Phase 1 studies with antiviral exposures achieved
Completed RSV challenge model with high potency against both viral load and symptoms
Excellent safety profile
Entering an international multicentre Phase 2 paediatric trial

Meet the team...